Literature DB >> 17175142

Effects of risperidone on dopamine receptor subtypes in developing rat brain.

Taylor Moran-Gates1, Christopher Grady, Young Shik Park, Ross J Baldessarini, Frank I Tarazi.   

Abstract

The atypical antipsychotic risperidone is often prescribed to pediatric patients with neuropsychiatric disorders, though its effects on the developing brain remain unclear. Accordingly, we studied the effects of repeated treatment of risperidone on dopamine receptors in brain regions of juvenile rat. Levels of dopamine receptors (D(1), D(2), D(3), D(4)) in forebrain regions of juvenile rats were quantified after 3 weeks of treatment with three different doses of risperidone (0.3, 1.0 and 3.0 mg/kg) and compared findings to those in adult rats treated with risperidone (3.0 mg/kg/day) previously. Risperidone (at 1.0 and 3.0 mg/kg/day) increased levels of D(1) receptors in nucleus accumbens and caudate-putamen of juvenile, but not adult rats. Conversely, all three doses of risperidone dose-dependently increased D(2) labeling in medial prefrontal cortex and hippocampus, and D(4) receptor in nucleus accumbens, caudate-putamen and hippocampus of juvenile animals as well as in adults. Only the high dose of risperidone (3.0 mg/kg) increased D(2) receptors in caudate-putamen in both juvenile and adult brain. D(3) receptors were not altered by risperidone in any brain region at any dose or age. The findings indicate dose-dependent effects of risperidone on dopamine receptors in developing animals, and that juvenile animals are more sensitive than adults to the cerebral effects of risperidone.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17175142      PMCID: PMC1931412          DOI: 10.1016/j.euroneuro.2006.10.004

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  44 in total

1.  Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.

Authors:  A Schotte; P F Janssen; W Gommeren; W H Luyten; P Van Gompel; A S Lesage; K De Loore; J E Leysen
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

Review 2.  The functional anatomy of basal ganglia disorders.

Authors:  R L Albin; A B Young; J B Penney
Journal:  Trends Neurosci       Date:  1989-10       Impact factor: 13.837

3.  Differential effects of clozapine and haloperidol on dopamine receptor mRNA expression in rat striatum and cortex.

Authors:  S P Damask; K A Bovenkerk; G de la Pena; K M Hoversten; D B Peters; A M Valentine; J H Meador-Woodruff
Journal:  Brain Res Mol Brain Res       Date:  1996-09-05

Review 4.  Metabolic side effects of atypical antipsychotics in children: a literature review.

Authors:  Valérie J Fedorowicz; Eric Fombonne
Journal:  J Psychopharmacol       Date:  2005-09       Impact factor: 4.153

Review 5.  Dopamine D4 receptors: beyond schizophrenia.

Authors:  Frank I Tarazi; Kehong Zhang; Ross J Baldessarini
Journal:  J Recept Signal Transduct Res       Date:  2004-08       Impact factor: 2.092

6.  Medial prefrontal cortical D2 and striatolimbic D4 dopamine receptors: common targets for typical and atypical antipsychotic drugs.

Authors:  F I Tarazi; S K Yeghiayan; J L Neumeyer; R J Baldessarini
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1998-05       Impact factor: 5.067

7.  Enhanced expression of dopamine D(1) and glutamate NMDA receptors in dopamine D(4) receptor knockout mice.

Authors:  Lu Gan; Tomas L Falzone; Kehong Zhang; Marcelo Rubinstein; Ross J Baldessarini; Frank I Tarazi
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

8.  Prolonged D2 antidopaminergic activity of alkylating and nonalkylating derivatives of spiperone in rat brain.

Authors:  R J Baldessarini; N S Kula; A Campbell; V Bakthavachalam; J Yuan; J L Neumeyer
Journal:  Mol Pharmacol       Date:  1992-11       Impact factor: 4.436

9.  Effectiveness of the selective D4 antagonist sonepiprazole in schizophrenia: a placebo-controlled trial.

Authors:  Mark H Corrigan; Christopher C Gallen; M Luisa Bonura; Kalpana M Merchant
Journal:  Biol Psychiatry       Date:  2004-03-01       Impact factor: 13.382

10.  D1 and D2 dopamine receptor-mediated mechanisms and behavioral supersensitivity.

Authors:  C Marin; S A Parashos; V Kapitzoglou-Logothetis; A Peppe; T N Chase
Journal:  Pharmacol Biochem Behav       Date:  1993-05       Impact factor: 3.533

View more
  14 in total

1.  Early-life risperidone enhances locomotor responses to amphetamine during adulthood.

Authors:  Bobbie Lee Stubbeman; Clifford J Brown; Justin R Yates; Mark E Bardgett
Journal:  Eur J Pharmacol       Date:  2017-07-14       Impact factor: 4.432

2.  Effects of repeated risperidone exposure on serotonin receptor subtypes in developing rats.

Authors:  Yong Kee Choi; Taylor Moran-Gates; Matthew P Gardner; Frank I Tarazi
Journal:  Eur Neuropsychopharmacol       Date:  2009-10-29       Impact factor: 4.600

3.  Risperidone administered during asymptomatic period of adolescence prevents the emergence of brain structural pathology and behavioral abnormalities in an animal model of schizophrenia.

Authors:  Yael Piontkewitz; Michal Arad; Ina Weiner
Journal:  Schizophr Bull       Date:  2010-05-03       Impact factor: 9.306

4.  In vitro-in vivo correlations of scalable PLGA-risperidone implants for the treatment of schizophrenia.

Authors:  Laura C Amann; Michael J Gandal; Robert Lin; Yuling Liang; Steven J Siegel
Journal:  Pharm Res       Date:  2010-04-27       Impact factor: 4.200

5.  Delayed yet persistent effects of daily risperidone on activity in developing rats.

Authors:  Rachel M Stevens; Matthew A Gannon; Molly S Griffith; Mark E Bardgett
Journal:  Behav Pharmacol       Date:  2016-08       Impact factor: 2.293

6.  Early-life risperidone administration alters maternal-offspring interactions and juvenile play fighting.

Authors:  Matthew A Gannon; Clifford J Brown; Rachel M Stevens; Molly S Griffith; Cecile A Marczinski; Mark E Bardgett
Journal:  Pharmacol Biochem Behav       Date:  2015-01-17       Impact factor: 3.533

7.  Long-lasting sensitization induced by repeated risperidone treatment in adolescent Sprague-Dawley rats: a possible D2 receptor mediated phenomenon?

Authors:  Jing Qiao; Jun Gao; Qing Shu; Qinglin Zhang; Gang Hu; Ming Li
Journal:  Psychopharmacology (Berl)       Date:  2013-12-21       Impact factor: 4.530

8.  Effects of risperidone on glutamate receptor subtypes in developing rat brain.

Authors:  Yong Kee Choi; Matthew P Gardner; Frank I Tarazi
Journal:  Eur Neuropsychopharmacol       Date:  2008-10-09       Impact factor: 4.600

9.  Adult rats treated with risperidone during development are hyperactive.

Authors:  Mark E Bardgett; Julie M Franks-Henry; Kristin R Colemire; Kathleen R Juneau; Rachel M Stevens; Cecile A Marczinski; Molly S Griffith
Journal:  Exp Clin Psychopharmacol       Date:  2013-06       Impact factor: 3.157

10.  Olanzapine treatment of adolescent rats causes enduring specific memory impairments and alters cortical development and function.

Authors:  Jean A Milstein; Ahmed Elnabawi; Monika Vinish; Thomas Swanson; Jennifer K Enos; Aileen M Bailey; Bryan Kolb; Douglas O Frost
Journal:  PLoS One       Date:  2013-02-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.